1,4,7-triazacyclononane-n,n',n''-triacetic acid has been researched along with arginyl-glycyl-aspartic acid in 16 studies
| Studies (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Trials (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Recent Studies (post-2010) (1,4,7-triazacyclononane-n,n',n''-triacetic acid) | Studies (arginyl-glycyl-aspartic acid) | Trials (arginyl-glycyl-aspartic acid) | Recent Studies (post-2010) (arginyl-glycyl-aspartic acid) |
|---|---|---|---|---|---|
| 195 | 3 | 161 | 4,556 | 17 | 1,799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (93.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, JK; Jeong, JM; Jeong, SY; Ju, CH; Kim, YJ; Lee, BC; Lee, DS; Lee, MC; Lee, YS | 1 |
| Decristoforo, C; Fani, M; Griessinger, CM; Haubner, R; Kesenheimer, C; Knetsch, PA; Petrik, M; Pichler, BJ; Rangger, C; Virgolini, I; von Guggenberg, E | 1 |
| Cheng, Z; Jiang, H; Liu, H; Liu, S; Xu, Y; Zhang, H | 1 |
| Baechler, S; Buchegger, F; Dunet, V; Kosinski, M; Poitry-Yamate, C; Prior, JO; Rüegg, C; Viertl, D | 1 |
| Chen, X; Guo, N; Kiesewetter, DO; Lang, L; Li, W; Ma, Y; Niu, G; Shen, B; Zhu, L | 1 |
| Han, SW; Jeong, JM; Kang, KW; Kim, JH; Kim, TY; Lee, DS; Lee, HY; Lee, JS; Lee, YS | 1 |
| Cao, F; Chen, X; Gao, H; Guo, N; Hu, S; Kiesewetter, DO; Lang, L; Niu, G; Quan, Q | 1 |
| Boros, E; Ferreira, CL; Gill, RK; Jurek, P; Kiefer, GE; Mandel, D; Wong, MQ; Yapp, DT | 1 |
| Chung, JK; Eo, JS; Jeong, JM; Kang, KW; Lee, DS; Lee, S; Lee, YS; Paeng, JC | 1 |
| Chen, X; Guo, J; Guo, N; Hu, S; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Sun, Z; Xie, Q; Zhu, L | 1 |
| Bandari, RP; Durkan, K; Hoffman, TJ; Jiang, Z; Liu, L; Miao, Y; Reynolds, TS; Rold, TL; Sieckman, GL; Smith, CJ; Szczodroski, AF | 1 |
| Chen, X; Kiesewetter, DO; Lang, L; Ma, Y | 1 |
| Ai, H; Chen, S; Cheng, Z; Jiang, X; Li, X; Lu, H; Qing, H; Wei, R; Wu, C; Xu, G | 1 |
| Chen, H; Chen, X; Jacobson, O; Kiesewetter, DO; Liu, Y; Ma, Y; Niu, G; Weiss, ID; Wu, H | 1 |
| Banach, M; Cole, JA; Czaplewska, P; Czerwinski, A; Dobrucki, IT; Dobrucki, LW; Hedhli, J; Hood, L; Imoukhuede, P; Kalinowski, L; Mamer, SB; Płoska, A; Schuelke, M; Sowinski, P | 1 |
| Kim, HS; Li, Z; Ludwig, J; Ma, Y; Sun, L; Zeng, D | 1 |
16 other study(ies) available for 1,4,7-triazacyclononane-n,n',n''-triacetic acid and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Development of a ¹⁷⁷Lu-labeled RGD derivative for targeting angiogenesis.
Topics: Animal Structures; Animals; Chelating Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Delivery Systems; Drug Stability; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Neovascularization, Pathologic; Oligopeptides; Radioisotopes; Radiopharmaceuticals; Tissue Distribution | 2010 |
[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Topics: Animals; Cell Line, Tumor; Coordination Complexes; Gene Expression Regulation; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Isotope Labeling; Mice; Oligopeptides; Peptides, Cyclic; Positron-Emission Tomography | 2011 |
One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD₂ for tumor angiogenesis PET imaging.
Topics: Animals; Cell Line, Tumor; Drug Stability; Female; Glioblastoma; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Integrins; Mice; Neovascularization, Pathologic; Oligopeptides; Positron-Emission Tomography; Radiochemistry | 2011 |
68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry.
Topics: Animals; Body Burden; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Metabolic Clearance Rate; Mice; Mice, Inbred ICR; Oligopeptides; Organ Specificity; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Whole-Body Counting | 2011 |
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice.
Topics: Animals; Cell Line, Tumor; Fluorine Radioisotopes; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Mice; Neoplasms; Oligopeptides; Positron-Emission Tomography | 2011 |
Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging.
Topics: Adult; Aged; Female; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neovascularization, Pathologic; Oligopeptides; Positron-Emission Tomography; Radiation Dosage; Radiometry; Radiopharmaceuticals; Tissue Distribution | 2012 |
PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2.
Topics: Animals; Coordination Complexes; Fluorine Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Neovascularization, Physiologic; Oligopeptides; Peptides, Cyclic; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Radiochemistry; Rats; Rats, Sprague-Dawley | 2012 |
(68)Ga small peptide imaging: comparison of NOTA and PCTA.
Topics: Animals; Cell Line, Tumor; Chlorobenzenes; Gallium Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Mice; Molecular Imaging; Molecular Structure; Oligopeptides; Positron-Emission Tomography; Tissue Distribution | 2012 |
Angiogenesis imaging in myocardial infarction using 68Ga-NOTA-RGD PET: characterization and application to therapeutic efficacy monitoring in rats.
Topics: Angiogenesis Inducing Agents; Animals; Coordination Complexes; Disease Models, Animal; Female; Fibroblast Growth Factor 2; Gallium Radioisotopes; Heart; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Myocardial Infarction; Neovascularization, Physiologic; Oligopeptides; Positron-Emission Tomography; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley | 2013 |
Comparison of three dimeric 18F-AlF-NOTA-RGD tracers.
Topics: Aluminum Compounds; Animals; Cell Line, Tumor; Dimerization; Fluorides; Fluorine Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Mice; Oligopeptides; Organ Specificity; Radioactive Tracers; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Topics: Aminocaproic Acid; Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Copper Radioisotopes; Dimerization; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Male; Mice; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radioactive Tracers; Receptors, Bombesin | 2014 |
Stability analysis of glutamic acid linked peptides coupled to NOTA through different chemical linkages.
Topics: Amides; Amines; Animals; Bombesin; Buffers; Chromatography, High Pressure Liquid; Chromatography, Liquid; Dimerization; Ethanol; Glutamic Acid; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrolysis; Mass Spectrometry; Mice; Oligopeptides; Peptides; Sulfhydryl Compounds; Temperature; Thiourea | 2014 |
Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Dideoxynucleosides; Disease Models, Animal; Fluorodeoxyglucose F18; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Male; Mice; Mice, Nude; Misonidazole; Multimodal Imaging; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Novel "Add-On" Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents.
Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Evans Blue; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Mice; Oligopeptides; Positron-Emission Tomography; Radiochemistry; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes | 2017 |
Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α
Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Dimerization; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Kidney; Mice; Neovascularization, Pathologic; Oligopeptides; Peptides, Cyclic; Positron-Emission Tomography; Rats; Tissue Distribution | 2017 |
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response.
Topics: Animals; CD8 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Copper Radioisotopes; Heterocyclic Compounds, 1-Ring; Immunotherapy; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oligopeptides; Positron-Emission Tomography; Sample Size | 2021 |